Last edition
News about Market
Integris Medtech Secures SEBI Nod for INR 925 Crore IPO
Integris Medtech, the second-largest Indian-headquartered diversified medical technology platform by operating revenue in FY25, has received approval from the Securities and Exchange Board of India (SEBI) to proceed with its proposed initial public offering (IPO).
Market | 25/02/2026 | By Darshana | 475
Frontier Biotechnologies Inc. Signs USD 1 Billion siRNA Licensing Deal with GSK
Frontier Biotech has granted GSK exclusive global rights to two siRNA drug candidates in a deal worth up to USD 1 billion, strengthening its international expansion and immunology pipeline focus.
Market | 25/02/2026 | By News Bureau | 408
Lupin Secures European Commission Approval for Ranluspec, Biosimilar Ranibizumab
European Commission clears Lupin’s biosimilar ranibizumab, Ranluspec, for multiple retinal disorders; Sandoz to commercialise across the EU, expanding access to affordable biologics.
Market | 24/02/2026 | By News Bureau | 198
Morepen Bags INR 825 Crore Global Deal
Morepen has secured a ?825 crore global deal, marking its expansion into the high-growth Contract Development and Manufacturing Organisation (CDMO) segment.
Market | 24/02/2026 | By News Bureau | 181
Exclusive licensing deal grants Arrotex rights to market clobetasol propionate ophthalmic suspension for post-surgical ocular inflammation and pain, expanding Formosa’s footprint in Oceania.
Market | 23/02/2026 | By News Bureau | 188
India, Brazil Ink MoU to Deepen Regulatory Cooperation in Pharma and Medical Products
India’s CDSCO and Brazil’s ANVISA exchanged MoU in the presence of Prime Minister Narendra Modi and President Luiz Inácio Lula da Silva to strengthen regulatory cooperation in pharmaceuticals and medical products.
Market | 23/02/2026 | By News Bureau | 189
Nektar Therapeutics and UCSF collaborate to study TNFR2 agonist NKTR-0165 in multiple sclerosis, aiming to explore its potential for neuroprotection and reduced neurodegeneration.
Market | 18/02/2026 | By News Bureau | 264
Simplified once-monthly schedule for RYBREVANT FASPRO matches bi-weekly efficacy, reduces clinic visits and maintains a strong safety profile.
Market | 18/02/2026 | By News Bureau | 165
Newron Pharmaceuticals Secures Euro 38 Million to Advance Phase III Schizophrenia Programme
Newron Pharmaceuticals strengthens its funding base with a multi-tranche equity raise to support late-stage development of evenamide in treatment-resistant schizophrenia.
Market | 17/02/2026 | By News Bureau | 196
Hikal Ltd posts quarterly loss as pharma manufacturing operations return to recovery
Hikal Ltd reported a net loss of INR 5.9 crore in the third quarter of FY26, compared with a profit of INR 17.2 crore in the corresponding quarter last year. Despite the loss, total revenue from operations increased 10.4 per cent year on year to INR 494.3 crore, up from INR 447.7 crore.
Market | 16/02/2026 | By Darshana | 213
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy